Antengene Unveils Promising Preclinical Findings for AnTenGager-D2 at SITC 2026

Antengene Presents Latest Breakthrough in T Cell Engagers

Antengene Corporation Limited, a prominent global biotech firm, has taken center stage at the Society for Immunotherapy of Cancer (SITC) 2026 by presenting groundbreaking preclinical results pertaining to its innovative costimulatory T cell engager (Cos-TCE) platform, named AnTenGager-D2. The presentation was part of the Rapid Oral Abstract sessions at the conference, and notably, it was selected as one of the top 150 abstracts by the organizers, underlining the significance of this research in the field.

Overview of AnTenGager-D2

AnTenGager-D2 represents a significant advancement in the treatment of various malignancies, particularly those that are challenging to address, such as solid tumors. Unlike traditional T cell engagers that primarily focus on CD3 targets, AnTenGager-D2 incorporates a multifaceted approach to T cell activation, providing dual signaling through CD3 and a newly integrated engineered CD2-binder, which is crucial in the activation process of T cells. This innovative mechanism allows greater potency in anti-tumor effects and minimizes drawbacks often caused by tumor microenvironments, such as T cell exhaustion and anergy.

This platform operates fundamentally on the premise that activating the CD2/CD58 interaction can enhance T cell responses significantly, overcoming barriers that have historically limited the effectiveness of cancer therapies.

Key Findings from the Research

At the heart of the study was a molecule developed from the AnTenGager-D2 platform, designated ATG-109 (KLK2×CD2×CD3). The researchers evaluated its in vitro anti-tumor potential, pharmacokinetics, and in vivo efficacy using a prostate cancer cell-derived xenograft model. The results were compelling. The characterization of the parental anti-CD3 antibodies revealed a notable specificity interacting with the CD3 heterodimer, supporting strong binding kinetics and reduced cytokine release compared to established CD3 antibody benchmarks.

Additionally, the engineered CD58 IgV proteins showed remarkable thermal stability and enhanced antibody-dependent cellular cytotoxicity (ADCC) against DLL3-positive tumor cells. One of the most striking data points was the impressive safety profile exhibited by the AnTenGager-D2 platform, marking it as a promising candidate for further clinical development.

ATG-109 displayed a significant efficacy boost when targeting KLK2 positive tumors, establishing itself as a powerful alternative in comparison to existing treatments that have inadequate safety margins. Furthermore, it demonstrated favorable pharmacokinetic characteristics, with a much longer half-life and exceptional thermal stability, which is crucial for maintaining efficacy during storage and administration.

Conclusion and Future Directions

Antengene's innovations through the AnTenGager-D2 platform indicate a promising future for therapies targeting T cell engagement in oncology. As the company prepares to advance ATG-109 through further preclinical studies, the results from SITC 2026 highlight the potential impact this technology could have on treating hematological malignancies and solid tumors alike. These developments are particularly exciting for patients with significant unmet medical needs, as Antengene continues its mission of pioneering revolutionary therapies that could change the standard of care in cancer treatment.

About Antengene Corporation

Antengene Corporation, publicly traded under SEHK: 6996.HK, is dedicated to creating innovative and effective therapeutic solutions for oncology and other severe diseases. The company boasts a broad investigational pipeline, evidencing its commitment to merging scientific innovation with patient care. Antengene’s proprietary T cell engager platform, AnTenGager®, exemplifies its forward-thinking approach, focusing on maximizing treatment efficacy while minimizing adverse effects.

With an increasing number of investigational approvals and a robust product portfolio, Antengene is poised to continue its growth as a key player in the global biotech landscape.